FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2122748744> ?p ?o ?g. }

• W2122748744 endingPage "1620" @default.
• W2122748744 startingPage "1616" @default.
• W2122748744 abstract "Background: The use of hetastarch during coronarybypass surgery has been limited due to its unresolved potentialrisk for hemorrhage. Therefore, the purpose of this study was toinvestigate the effects of using 6% hetastarch in primingcardiopulmonary bypass (CPB) circuitry on the need for blood producttransfusions and outcome after coronary bypass. Materialsand methods: This nonrandomized retrospective study involved 887patients who underwent isolated primary coronary artery bypassgrafting. Based on the type of solution used in priming the CPBcircuitry, patients were stratified into the following four differentgroups: group 1, crystalloid (500 m, L; n = 211); group 2, 25% humanalbumin (50 m, L; n = 217); group 3, 6% hetastarch (500 m, L; n = 298); and group 4, 25% human albumin (50 m, L) and 6% hetastarch(500 m, L; n = 161). Patient characteristics and clinicalvariables were compared among the groups using the Kruskal-Wallis test. Patient survival estimates were compared using log-ranktest. Results: Demographic patientcharacteristics for all groups were similar (p > 0.05).Intraoperative and perioperative variables among groups were comparable(p > 0.05). The use of hetastarch as a part of prime solution in CPBcircuitry did not alter the need for banked blood, platelets, or freshfrozen plasma transfusions (p > 0.05). The length of stay in the ICUor in the hospital was unaffected in all groups. The early(ie, 30-day) mortality rate was 1.4% in group 1, 1.8% in group 2, 1.0% in group 3, and 3.1% in group 4. Long-term survivalamong the groups was unaffected by the type of priming solution. Conclusions: The use of hetastarch in priming CPB circuitryis devoid of any added hemorrhagic risk after coronary bypass, and thetype of prime solution for CPB has no influence on the early or latesurvival rates of patients undergoing primary coronarybypass. The use of hetastarch during coronarybypass surgery has been limited due to its unresolved potentialrisk for hemorrhage. Therefore, the purpose of this study was toinvestigate the effects of using 6% hetastarch in primingcardiopulmonary bypass (CPB) circuitry on the need for blood producttransfusions and outcome after coronary bypass. This nonrandomized retrospective study involved 887patients who underwent isolated primary coronary artery bypassgrafting. Based on the type of solution used in priming the CPBcircuitry, patients were stratified into the following four differentgroups: group 1, crystalloid (500 m, L; n = 211); group 2, 25% humanalbumin (50 m, L; n = 217); group 3, 6% hetastarch (500 m, L; n = 298); and group 4, 25% human albumin (50 m, L) and 6% hetastarch(500 m, L; n = 161). Patient characteristics and clinicalvariables were compared among the groups using the Kruskal-Wallis test. Patient survival estimates were compared using log-ranktest. Demographic patientcharacteristics for all groups were similar (p > 0.05).Intraoperative and perioperative variables among groups were comparable(p > 0.05). The use of hetastarch as a part of prime solution in CPBcircuitry did not alter the need for banked blood, platelets, or freshfrozen plasma transfusions (p > 0.05). The length of stay in the ICUor in the hospital was unaffected in all groups. The early(ie, 30-day) mortality rate was 1.4% in group 1, 1.8% in group 2, 1.0% in group 3, and 3.1% in group 4. Long-term survivalamong the groups was unaffected by the type of priming solution. The use of hetastarch in priming CPB circuitryis devoid of any added hemorrhagic risk after coronary bypass, and thetype of prime solution for CPB has no influence on the early or latesurvival rates of patients undergoing primary coronarybypass." @default.
• W2122748744 created "2016-06-24" @default.
• W2122748744 creator A5028394457 @default.
• W2122748744 creator A5039281835 @default.
• W2122748744 date "2000-12-01" @default.
• W2122748744 modified "2023-09-29" @default.
• W2122748744 title "Use of Intraoperative Hetastarch Priming During Coronary Bypass" @default.
• W2122748744 cites W196639880 @default.
• W2122748744 cites W1982201239 @default.
• W2122748744 cites W1987198195 @default.
• W2122748744 cites W1987421741 @default.
• W2122748744 cites W2006760464 @default.
• W2122748744 cites W2012816048 @default.
• W2122748744 cites W2037301086 @default.
• W2122748744 cites W2065285118 @default.
• W2122748744 cites W2078171732 @default.
• W2122748744 cites W4294553798 @default.
• W2122748744 cites W63846988 @default.
• W2122748744 doi "https://doi.org/10.1378/chest.118.6.1616" @default.
• W2122748744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11115448" @default.
• W2122748744 hasPublicationYear "2000" @default.
• W2122748744 type Work @default.
• W2122748744 sameAs 2122748744 @default.
• W2122748744 citedByCount "18" @default.
• W2122748744 countsByYear W21227487442012 @default.
• W2122748744 countsByYear W21227487442013 @default.
• W2122748744 crossrefType "journal-article" @default.
• W2122748744 hasAuthorship W2122748744A5028394457 @default.
• W2122748744 hasAuthorship W2122748744A5039281835 @default.
• W2122748744 hasConcept C100701293 @default.
• W2122748744 hasConcept C141071460 @default.
• W2122748744 hasConcept C2776820930 @default.
• W2122748744 hasConcept C2779412105 @default.
• W2122748744 hasConcept C2909252273 @default.
• W2122748744 hasConcept C31174226 @default.
• W2122748744 hasConcept C42219234 @default.
• W2122748744 hasConcept C59822182 @default.
• W2122748744 hasConcept C71924100 @default.
• W2122748744 hasConcept C81444415 @default.
• W2122748744 hasConcept C86803240 @default.
• W2122748744 hasConceptScore W2122748744C100701293 @default.
• W2122748744 hasConceptScore W2122748744C141071460 @default.
• W2122748744 hasConceptScore W2122748744C2776820930 @default.
• W2122748744 hasConceptScore W2122748744C2779412105 @default.
• W2122748744 hasConceptScore W2122748744C2909252273 @default.
• W2122748744 hasConceptScore W2122748744C31174226 @default.
• W2122748744 hasConceptScore W2122748744C42219234 @default.
• W2122748744 hasConceptScore W2122748744C59822182 @default.
• W2122748744 hasConceptScore W2122748744C71924100 @default.
• W2122748744 hasConceptScore W2122748744C81444415 @default.
• W2122748744 hasConceptScore W2122748744C86803240 @default.
• W2122748744 hasIssue "6" @default.
• W2122748744 hasLocation W21227487441 @default.
• W2122748744 hasLocation W21227487442 @default.
• W2122748744 hasOpenAccess W2122748744 @default.
• W2122748744 hasPrimaryLocation W21227487441 @default.
• W2122748744 hasRelatedWork W1445005253 @default.
• W2122748744 hasRelatedWork W1580905093 @default.
• W2122748744 hasRelatedWork W1691826783 @default.
• W2122748744 hasRelatedWork W2050964318 @default.
• W2122748744 hasRelatedWork W2137924411 @default.
• W2122748744 hasRelatedWork W2296069129 @default.
• W2122748744 hasRelatedWork W2348467774 @default.
• W2122748744 hasRelatedWork W2386203827 @default.
• W2122748744 hasRelatedWork W2392407047 @default.
• W2122748744 hasRelatedWork W2766707884 @default.
• W2122748744 hasVolume "118" @default.
• W2122748744 isParatext "false" @default.
• W2122748744 isRetracted "false" @default.
• W2122748744 magId "2122748744" @default.
• W2122748744 workType "article" @default.